| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1111/J.1365-3024.2006.00808.X |
| P698 | PubMed publication ID | 16438676 |
| P2093 | author name string | Marsh K | |
| Kinyanjui S | |||
| P433 | issue | 1-2 | |
| P921 | main subject | malaria | Q12156 |
| P304 | page(s) | 51-60 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Parasite Immunology | Q15751559 |
| P1476 | title | Immune effector mechanisms in malaria | |
| P478 | volume | 28 |
| Q24600538 | A plethora of Plasmodium species in wild apes: a source of human infection? |
| Q33802641 | A positive correlation between atypical memory B cells and Plasmodium falciparum transmission intensity in cross-sectional studies in Peru and Mali |
| Q37124766 | Acquired antibodies to merozoite antigens in children from Uganda with uncomplicated or severe Plasmodium falciparum malaria |
| Q37220749 | Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in Children |
| Q33380204 | Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum |
| Q40102134 | Acquisition, maintenance and adaptation of invasion inhibitory antibodies against Plasmodium falciparum invasion ligands involved in immune evasion |
| Q28744149 | Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults |
| Q28744136 | Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component |
| Q21032463 | Advances and challenges in malaria vaccine development |
| Q34145333 | Advances and challenges in malaria vaccine development. |
| Q33289532 | Age-adjusted Plasmodium falciparum antibody levels in school-aged children are a stable marker of microgeographical variations in exposure to Plasmodium infection |
| Q46225955 | Age-dependent association between IgG2 and IgG3 subclasses to Pf332-C231 antigen and protection from malaria, and induction of protective antibodies by sub-patent malaria infections, in Daraweesh |
| Q34063541 | Amplification of P. falciparum Cytoadherence through induction of a pro-adhesive state in host endothelium |
| Q47150417 | An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies |
| Q37191417 | Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure |
| Q35016677 | Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic |
| Q35569042 | Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria |
| Q34827195 | Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria |
| Q34142748 | Antibody recognition of Plasmodium falciparum infected red blood cells by symptomatic and asymptomatic individuals in the Brazilian Amazon. |
| Q40059998 | Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso |
| Q61805875 | Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure |
| Q33380213 | Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults |
| Q37274832 | Approaches to malaria vaccine development using the retrospectroscope |
| Q34257253 | Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure |
| Q35328464 | Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda |
| Q35965161 | Asymptomatic Multiclonal Plasmodium falciparum Infections Carried Through the Dry Season Predict Protection Against Subsequent Clinical Malaria |
| Q37269963 | Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area |
| Q36651730 | B cell sub-types following acute malaria and associations with clinical immunity |
| Q35684739 | CD14(hi)CD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so |
| Q27318165 | CD19(+) B cells confer protection against experimental cerebral malaria in semi-immune rodent model |
| Q37256445 | Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea |
| Q47916186 | Changes in cell migration-related molecules expressed by thymic microenvironment during experimental Plasmodium berghei infection: consequences on thymocyte development. |
| Q91729483 | Changing plasma cytokine, chemokine and growth factor profiles upon differing malaria transmission intensities |
| Q37557832 | Chapter 5. Potential contribution of sero-epidemiological analysis for monitoring malaria control and elimination: historical and current perspectives |
| Q37606588 | Characterization of Caveola-Vesicle Complexes (CVCs) Protein, PHIST/CVC-8195 in Plasmodium vivax |
| Q44168441 | Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine |
| Q36545994 | Chronic Exposure to Plasmodium falciparum Is Associated with Phenotypic Evidence of B and T Cell Exhaustion |
| Q33548663 | Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies |
| Q48021901 | Cutting Edge: Plasmodium falciparum Induces Trained Innate Immunity. |
| Q41438284 | Cytotoxic activities of CD8⁺ T cells collaborate with macrophages to protect against blood-stage murine malaria |
| Q36423357 | Decision-making on malaria vaccine introduction: the role of cost-effectiveness analyses |
| Q41995596 | Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study |
| Q41991578 | Declining malaria transmission differentially impacts on the maintenance of humoral immunity to Plasmodium falciparum in children |
| Q36886734 | Delayed acquisition of Plasmodium falciparum antigen-specific CD4(+) T cell responses in HIV-exposed uninfected Malawian children receiving daily cotrimoxazole prophylaxis |
| Q38089185 | Development of influenza virosome-based synthetic malaria vaccines |
| Q35684692 | Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens |
| Q33530114 | Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children |
| Q39230991 | Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance |
| Q33913006 | Dynamics in multiplicity of Plasmodium falciparum infection among children with asymptomatic malaria in central Ghana |
| Q40731405 | Early effector cells survive the contraction phase in malaria infection and generate both central and effector memory T cells |
| Q34732640 | Effect of HIV infection on the acute antibody response to malaria antigens in children: an observational study |
| Q33733730 | Effect of IPTp on Plasmodium falciparum antibody levels among pregnant women and their babies in a sub-urban coastal area in Ghana |
| Q35017067 | Effects of age, hemoglobin type and parasite strain on IgG recognition of Plasmodium falciparum-infected erythrocytes in Malian children |
| Q92280942 | Effects of malaria/helminthic coinfections on cervical cancer progression among sub Saharan African women on highly active antiretroviral therapy: A scoping review |
| Q34540211 | Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites |
| Q48006742 | Endogenous galectin‐3 controls experimental malaria in a species‐specific manner |
| Q36950025 | Enhanced toll-like receptor responsiveness associated with mitogen-activated protein kinase activation in Plasmodium falciparum-infected children |
| Q47986453 | Evaluation of the genetic diversity of domain II of Plasmodium vivax Apical Membrane Antigen 1 (PvAMA-1) and the ensuing strain-specific immune responses in patients from Sri Lanka |
| Q33336415 | Evidence for over-dispersion in the distribution of clinical malaria episodes in children |
| Q42702379 | Exposure of the Plasmodium falciparum clonally variant STEVOR proteins on the merozoite surface |
| Q35152209 | Exposure-dependent control of malaria-induced inflammation in children |
| Q55248535 | Factors influencing the induction of high affinity antibodies to Plasmodium falciparum merozoite antigens and how affinity changes over time. |
| Q34994491 | Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein |
| Q90681084 | Fluctuations of Spleen Cytokine and Blood Lactate, Importance of Cellular Immunity in Host Defense Against Blood Stage Malaria Plasmodium yoelii |
| Q34177302 | Gammadelta T cells but not NK cells are essential for cell-mediated immunity against Plasmodium chabaudi malaria |
| Q36687352 | Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA |
| Q58089797 | Genetic sequence characterization and naturally acquired immune response to Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) |
| Q28473154 | Genistein-supplemented diet decreases malaria liver infection in mice and constitutes a potential prophylactic strategy |
| Q40244549 | Genome-wide significant linkage to IgG subclass responses against Plasmodium falciparum antigens on chromosomes 8p22-p21, 9q34 and 20q13. |
| Q50983969 | Gradual acquisition of immunity to severe malaria with increasing exposure |
| Q37187464 | Hepatosplenomegaly associated with chronic malaria exposure: evidence for a pro-inflammatory mechanism exacerbated by schistosomiasis |
| Q34171724 | High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria |
| Q36726723 | High road, low road? Choices and challenges on the pathway to a malaria vaccine |
| Q36838314 | How Should Antibodies againstP. falciparumMerozoite Antigens Be Measured? |
| Q59806965 | Human Vγ9Vδ2 T Lymphocytes in the Immune Response to Infection |
| Q37458864 | IFNγ/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children |
| Q64054791 | Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain |
| Q35739115 | Identifying children with excess malaria episodes after adjusting for variation in exposure: identification from a longitudinal study using statistical count models |
| Q89571059 | IgG antibody response against Plasmodium falciparum aminopeptidase 1 antigen in Gabonese children living in Makokou and Franceville |
| Q91835699 | IgM+ memory B cells induced in response to Plasmodium berghei adopt a germinal centre B cell phenotype during secondary infection |
| Q40259888 | Immune Responses in Malaria |
| Q38689264 | Immunity to malaria in an era of declining malaria transmission |
| Q37194482 | Immunity to malaria: more questions than answers |
| Q89559305 | Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial |
| Q36053587 | Immunization with the MAEBL M2 Domain Protects against Lethal Plasmodium yoelii Infection |
| Q47840844 | Immunogenicity and protection-inducing ability of recombinant Plasmodium vivax rhoptry-associated protein 2 in Aotus monkeys: a potential vaccine candidate. |
| Q34025033 | Immunological consequences of intermittent preventive treatment against malaria in Senegalese preschool children |
| Q34234390 | Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis |
| Q33521372 | Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data |
| Q38690037 | Immunological processes underlying the slow acquisition of humoral immunity to malaria |
| Q46140366 | Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model |
| Q36707922 | Immunoproteomic analysis of Plasmodium falciparum antigens using sera from patients with clinical history of imported malaria. |
| Q90413679 | Improving Accuracy of Malaria Diagnosis in Underserved Rural and Remote Endemic Areas of Sub-Saharan Africa: A Call to Develop Multiplexing Rapid Diagnostic Tests |
| Q33613892 | In vitro growth-inhibitory activity and malaria risk in a cohort study in mali |
| Q36552347 | Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda |
| Q63363286 | Infection-Induced Resistance to Experimental Cerebral Malaria Is Dependent Upon Secreted Antibody-Mediated Inhibition of Pathogenic CD8 T Cell Responses |
| Q37355849 | Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam |
| Q35098216 | Innate immunity induced by Plasmodium liver infection inhibits malaria reinfections |
| Q41938035 | Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity |
| Q47925938 | Involvement of CD8+ T cells in protective immunity against murine blood-stage infection with Plasmodium yoelii 17XL strain |
| Q35199926 | Liver-Stage Specific Response among Endemic Populations: Diet and Immunity |
| Q33967206 | Long-lived Plasmodium falciparum specific memory B cells in naturally exposed Swedish travelers |
| Q35586865 | Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans |
| Q40592413 | Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity |
| Q56378965 | Malaria |
| Q28080325 | Malaria Parasites: The Great Escape |
| Q40055950 | Malaria Pathogenesis |
| Q33821137 | Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease |
| Q38854831 | Malaria vaccines and human immune responses |
| Q37039113 | Malaria-Cutaneous Leishmaniasis Co-infection: Influence on Disease Outcomes and Immune Response |
| Q36565070 | Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting |
| Q36531046 | Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malaria |
| Q47396685 | Mechanisms of naturally acquired immunity to P. falciparum and approaches to identify merozoite antigen targets |
| Q34261333 | Memory B cells are a more reliable archive for historical antimalarial responses than plasma antibodies in no-longer exposed children |
| Q40055186 | Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria |
| Q33400526 | Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. |
| Q91994696 | Microscopic and submicroscopic Plasmodium infections in indigenous and non-indigenous communities in Colombia |
| Q35076906 | Natural antibody response to Plasmodium falciparum merozoite antigens MSP5, MSP9 and EBA175 is associated to clinical protection in the Brazilian Amazon |
| Q33818748 | Natural regulatory T cells in malaria: host or parasite allies? |
| Q36751523 | Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection |
| Q38613292 | Naturally acquired antibody response to Plasmodium falciparum describes heterogeneity in transmission on islands in Lake Victoria |
| Q92547287 | Naturally acquired immunity against immature Plasmodium falciparum gametocytes |
| Q48083618 | New advances in molecular epizootiology of canine hematic protozoa from Venezuela, Thailand and Spain |
| Q35216634 | New antigens for a multicomponent blood-stage malaria vaccine |
| Q36330969 | New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women |
| Q21131082 | Novel approaches to identify protective malaria vaccine candidates |
| Q31169310 | Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria |
| Q31139546 | Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria |
| Q89835598 | Pattern of antibody responses to Plasmodium falciparum antigens in individuals differentially exposed to Anopheles bites |
| Q37115211 | Performance of microscopy and RDTs in the context of a malaria prevalence survey in Angola: a comparison using PCR as the gold standard |
| Q33558847 | Phenotypic characterization of Plasmodium berghei responsive CD8+ T cells after immunization with live sporozoites under chloroquine cover |
| Q34333912 | Plasmodium coatneyi in Rhesus Macaques Replicates the Multisystemic Dysfunction of Severe Malaria in Humans |
| Q92664225 | Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort |
| Q34419934 | Plasmodium immunomics. |
| Q35725321 | Plasmodium riboprotein PfP0 induces a deviant humoral immune response in Balb/c mice |
| Q37405958 | Post-exposure serological responses to malaria parasites in potential blood donors |
| Q34303373 | Predicting antidisease immunity using proteome arrays and sera from children naturally exposed to malaria |
| Q92666131 | Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review |
| Q35784187 | Primary infection of C57BL/6 mice with Plasmodium yoelii induces a heterogeneous response of NKT cells |
| Q26800494 | Profiling the host response to malaria vaccination and malaria challenge |
| Q37025030 | Progress and prospects for blood-stage malaria vaccines |
| Q34081745 | Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans |
| Q30248811 | Recent insights into humoral immunity targeting Plasmodium falciparum and Plasmodium vivax malaria |
| Q87860655 | Recombinant proteins of Plasmodium malariae merozoite surface protein 1 (PmMSP1): Testing immunogenicity in the BALB/c model and potential use as diagnostic tool. |
| Q64096896 | Repeated clinical malaria episodes are associated with modification of the immune system in children |
| Q33697651 | Schistosomiasis coinfection in children influences acquired immune response against Plasmodium falciparum malaria antigens |
| Q92993594 | Signatures of divergent anti-malarial treatment responses in peripheral blood from adults and young children in Malawi |
| Q64062058 | Single-molecule imaging and quantification of the immune-variant adhesin VAR2CSA on knobs of -infected erythrocytes |
| Q34221892 | Specific antibody responses against membrane proteins of erythrocytes infected by Plasmodium falciparum of individuals briefly exposed to malaria |
| Q36064542 | Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria |
| Q35752634 | Stool microbiota composition is associated with the prospective risk of Plasmodium falciparum infection |
| Q37333369 | Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children |
| Q33959038 | Strategies for designing and monitoring malaria vaccines targeting diverse antigens |
| Q35632820 | Superinfection in malaria: Plasmodium shows its iron will |
| Q34161839 | Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates |
| Q21032488 | Systems immunology of human malaria |
| Q64990601 | TH1-Polarized TFH Cells Delay Naturally-Acquired Immunity to Malaria. |
| Q36728063 | Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children |
| Q36190707 | Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity |
| Q22061808 | That Was Then But This Is Now: Malaria Research in the Time of an Eradication Agenda |
| Q56341482 | The 2015-2016 malaria epidemic in Northern Uganda; what are the implications for malaria control interventions? |
| Q33587496 | The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections |
| Q27348351 | The Role of Animal Models for Research on Severe Malaria |
| Q37239883 | The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria |
| Q34241973 | The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody |
| Q38127456 | The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum |
| Q35217416 | The effect of daily co-trimoxazole prophylaxis on natural development of antibody-mediated immunity against P. falciparum malaria infection in HIV-exposed uninfected Malawian children |
| Q36142172 | The effect of declining exposure on T cell-mediated immunity to Plasmodium falciparum - an epidemiological "natural experiment". |
| Q38068789 | The enigma of memory B cells in malaria |
| Q37616968 | The epidemiology of polyparasitism and implications for morbidity in two rural communities of Côte d'Ivoire |
| Q37471465 | The future for blood-stage vaccines against malaria |
| Q35304594 | The hunt for protective correlates of immunity to Plasmodium falciparum malaria |
| Q34600408 | The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan children |
| Q33526349 | The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis |
| Q37444734 | The relationship of Plasmodium falciparum humeral immunity with HIV-1 immunosuppression and treatment efficacy in Zambia |
| Q37088901 | The risk of malarial infections and disease in Papua New Guinean children. |
| Q94460590 | The role of complement immune response on artemisinin-based combination therapy in a population from malaria endemic region of Western Kenya |
| Q35579613 | The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area |
| Q33508230 | The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial |
| Q28551712 | Therapeutic Efficacy of Artemether-Lumefantrine (Coartem®) in Treating Uncomplicated P. falciparum Malaria in Metehara, Eastern Ethiopia: Regulatory Clinical Study |
| Q48022024 | Tissue-specific immunopathology during malaria infection |
| Q39323868 | Toll-like receptor 9 (TLR9) polymorphism associated with symptomatic malaria: a cohort study |
| Q34060022 | Transplacentally transferred functional antibodies against Plasmodium falciparum decrease with age |
| Q39364891 | Treatment of Chronic Asymptomatic Plasmodium falciparum Infection Does Not Increase the Risk of Clinical Malaria Upon Reinfection |
| Q34988452 | Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum |
| Q36413834 | Vaccine candidate discovery for the next generation of malaria vaccines. |
| Q17485685 | Vaccines against malaria |
| Q37520196 | Value of Plasmodium falciparum histidine-rich protein 2 level and malaria retinopathy in distinguishing cerebral malaria from other acute encephalopathies in Kenyan children |
| Q36227228 | Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies |
| Q37413044 | What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity |
| Q27687235 | Young lives lost as B cells falter: what we are learning about antibody responses in malaria |
| Q36287280 | Zinc finger nuclease-based double-strand breaks attenuate malaria parasites and reveal rare microhomology-mediated end joining |
Search more.